|
|
|
| Analysis of the clinical efficacy of intrauterine perfusion of growth hormone combined with hormone replacement therapy for treating women with thin endometrium after the frozen thawed embryo transfer |
| The First Affiliated Hospital of Xi'an Medical College, Xi'an, Shaanxi Province, 710082 |
|
|
|
|
Abstract To study the clinical efficacy of intrauterine perfusion of growth hormone (GH) combined with hormone replacement therapy (HRT) for treating women with thin endometrium (TE) after the frozen thawed embryo transfer. Methods: The clinical data of 90 infertile women who received in vitro fertilization-frozen thawed embryo transfer (IVF-FET) between July 2019 and July 2020 were analyzed retrospectively. According to the different endometrial preparation regimens, these women were divided into 38 cases with nature circle in group A and 52 cases with HRT cycle in group B. The women in both groups were given intrauterine perfusion of GH, and on this basis, the women in group A was given natural cycle and the women in group B were given HRT cycle. The endometrial thickness and blood flow signal of the women were compared between the two groups. When the endometrial thickness of the women in the two groups was ≥7 mm, the blastomere was thawed and the embryo transfer was performed for these women. The pregnancy status of the women in the two groups was observed. Results: The endometrial thickness of the women in the two groups in 1d before FET was significant thicker than that in the first day of the admission of drug, and the values of vascular resistance index (RI), pulse index (PI), and the ratio of end-systolic/end-diastolic blood flow velocity (S/D) of the women in the two groups in 1d before FET were significantly lower than those of the women in the first day of the admission of drug, and the changes of which of the women in group B were significantly greater than those of the women in group A (all P＜0.05). The serum E2 level (1823.74±206.19 pg/ml) and the clinical pregnancy rate (62.0%) of the women in group B in 1d before FET were significantly higher than those (1095.38±145.82 pg/ml and 38.7%) of the women in group A, and the cycle cancellation rate (3.9%) of the women in group B in 1d before FET was significantly lower than that (18.4%) of the women in group A (all P＜0.05). Conclusion: Intrauterine perfusion of GH combined with HRT for treating women with TE can promote their endometrial growth and improve their blood circulation, and help to reduce their cycle cancellation rate and increase their clinical pregnancy rate after FET, which has positive effect on their FET treatment.
|
|
|
|
|
|
|
|
|
